| Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans. | |
| | |
MedLine Citation:
|
PMID: 23292344 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVES: In this study we investigated the in vitro fungistatic and fungicidal activities of CPA18 and CPA109, two azole compounds with original structural features, alone and in combination with fluconazole against fluconazole-susceptible and -resistant Candida albicans strains. METHODS: Antifungal activities were measured by MIC evaluation and time-kill studies. Azole binding analysis was performed by UV-Vis spectroscopy. Hyphal growth inhibition and filipin and propidium iodide staining assays were used for morphological analysis. An analysis of membrane lipids was also performed to gauge alterations in membrane composition and integrity. Synergism was calculated using fractional inhibitory concentration indices (FICIs). Evaluation of cytotoxicity towards murine macrophages was performed to verify selective antifungal activity. RESULTS: Even though their binding affinity to C. albicans Erg11p is comparable to that of fluconazole, CPA compounds are active against resistant strains of C. albicans with a mutation in ERG11 sequences and/or overexpressing the ABC transporter genes CDR1 and CDR2, which encode ATP-dependent efflux pumps. Moreover, CPA18 is fungistatic, even against the two resistant strains, and was found to be synergistic with fluconazole. Differently from fluconazole and other related azoles, CPA compounds induced marked changes in membrane permeability and dramatic alterations in membrane lipid composition. CONCLUSIONS: Our outcomes suggest that CPA compounds are able to overcome major mechanisms of resistance in C. albicans. Also, they are promising candidates for combination treatment that could reduce the toxicity caused by high fluconazole doses, particularly in immunocompromised patients. |
| | |
Authors:
|
Elena C Calabrese; Sabrina Castellano; Marisabella Santoriello; Cristina Sgherri; Mike F Quartacci; Lucia Calucci; Andrew G S Warrilow; David C Lamb; Steven L Kelly; Ciro Milite; Ilaria Granata; Gianluca Sbardella; Giorgio Stefancich; Bruno Maresca; Amalia Porta |
Related Documents
:
|
3597204 - Cell surface hydrophobicity and charge of staphylococcus aureus and coagulase-negative ... 19672654 - Rapid colonization with methicillin-resistant coagulase-negative staphylococci after su... 15941774 - The antibacterial activity of honey against coagulase-negative staphylococci. 6512254 - Frequency of isolation of enterotoxigenic staphylococci from milk of nursing mothers in... 16825644 - Rhodovulum marinum sp. nov., a novel phototrophic purple non-sulfur alphaproteobacteriu... 22244984 - An n-halamine-based rechargeable antimicrobial and biofilm controlling polyurethane. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-7 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: - ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Pharmaceutical and Biomedical Sciences, University of Salerno, 84084 Fisciano, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The evolution of RuBisCO stability at the thermal limit of photoautotrophy.
Next Document: A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrol.